For research use only. Not for therapeutic Use.
Samatasvir（Cat No.:I035963）is an oral antiviral drug used in the treatment of chronic hepatitis C virus (HCV) infection. It is a potent, direct-acting antiviral (DAA) that specifically targets the NS5A protein, which plays a critical role in HCV replication and assembly. By inhibiting NS5A, Samatasvir disrupts the viral life cycle, reducing viral load and aiding in the clearance of the infection. It is often used in combination with other antiviral agents, enhancing therapeutic efficacy. Samatasvir offers an important treatment option in HCV management, contributing to sustained virologic response (SVR) in patients.
| Catalog Number | I035963 |
| CAS Number | 1312547-19-5 |
| Synonyms | Samatasvir; IDX 18719; IDX-18719; IDX18719; IDX 719; IDX-719; IDX719; |
| Molecular Formula | C47H48N8O6S2 |
| Purity | 98% |
| Target | Metabolic Enzyme/Protease |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 4°C, protect from light |
| IUPAC Name | methyl N-[(1R)-2-[(2S)-2-[5-[4-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]thieno[3,2-b]thiophen-3-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate |
| InChI | InChI=1S/C47H48N8O6S2/c1-26(2)38(52-46(58)60-3)44(56)55-21-9-13-37(55)43-49-33-19-18-30(22-34(33)50-43)32-25-63-40-31(24-62-41(32)40)27-14-16-28(17-15-27)35-23-48-42(51-35)36-12-8-20-54(36)45(57)39(53-47(59)61-4)29-10-6-5-7-11-29/h5-7,10-11,14-19,22-26,36-39H,8-9,12-13,20-21H2,1-4H3,(H,48,51)(H,49,50)(H,52,58)(H,53,59)/t36-,37-,38-,39+/m0/s1 |
| InChIKey | ATOLIHZIXHZSBA-BTSKBWHGSA-N |
| SMILES | CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CSC5=C4SC=C5C6=CC=C(C=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)NC(=O)OC |
| Reference | 1: Vince B, Hill JM, Lawitz EJ, O’Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. Epub 2014 Jan 14. PubMed PMID: 24434503. |
